Searched for
PHARMA TRAC
India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...- ORS sales melt in March after govt's stricter labelling normsIndia’s oral rehydration solution (ORS) market has declined after regulatory action restricted the labelling of sugary drinks as ORS, affec...
- Quadria, PE funds eye stake in Samarth Lifesciences; deal may value firm at Rs 4,500 croreQuadria Capital is eyeing a strategic acquisition of a majority interest in Samarth Lifesciences, a move that could value the transaction a...
- Weight-loss drug craze for Ozempic, Mounjaro surges in India amid safety concernsIn India, appetite for weight-loss drugs is on the rise, with consumers increasingly turning to injectables such as Mounjaro and Ozempic fo...
- Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
- Cancer drug makers seek 50% price hike as platinum surge hits production viabilityLocal drug manufacturers are struggling to produce essential cancer medicines like carboplatin and cisplatin due to a significant surge in ...
- Slimmer price tag helps Wegovy sales gain weightNovo Nordisk has slashed Wegovy prices in India by nearly 40 percent. This move has dramatically increased sales volume by 70 percent in No...
- Under the scanner, yet generic cough syrups hit shelvesWorry is spreading regarding the multitude of cough syrup brands circulating in India, with alarming revelations of toxic diethylene glycol...
- Mounjaro crosses Rs 50 cr in India in 90 days as Wegovy joins frayMounjaro, Eli Lilly's weight-loss drug, witnessed a massive sales jump in India since March. Sales reached ₹26 crore in June. Wegovy from N...
- Mercury soars, and so do sales of rehydration drinks in IndiaIndia is experiencing a surge in demand for dehydration-preventing drinks due to the intense heatwave. Electral sales have jumped 27% in Ma...
- Global companies account for 60% of Indian vaccine sales by valueIndia's vaccine market is steadily recovering after the impact from Covid-19 and multinationals are back to slowly gaining traction, sugges...
- Pharma market grows 9.5% in JanuaryThe Indian pharmaceutical market (IPM) saw a robust growth of 9.5% in January with all major therapy areas recording double-digit growth. A...
- Government prohibits 328 fixed dose combinationsThe ban is effective immediately and may shave off over Rs 1,500 crore from India’s Rs 1.18 lakh crore pharmaceutical industry
- Unichem Labs under regulator scanner for launching blood pressure medicines without price approvalAccording to NPPA, Unichem launched these medicines over four years before it applied to the regulator for price fixation.
- Popular antacid samples fail quality tests, company claims they were counterfeitsThe Pantocid and Pantocid DSR tested by CDSCO were not manufactured by Sun Pharma, the official spokesperson for the Mumbai-based drug make...
- Cipla aims to reach $1bn India sales through tie-upsCipla has stepped up launch plans in areas like respiratory, dermatology, cardiovascular and urology, which will help speed up its India gr...
- Prices of 98 drugs not fixed due to non availability of informationThe central government has not been able to fix the price of 98 drugs used for treating various diseases such as tuberculosis, cardiac cond...
- Domestic Pharma Growth Improves for the month of MaySequentially, the domestic pharma industry staged an improvement for the month of May. At 9.9%, according to data compiled by PharmaTrac
- Domestic pharma growth rebounds for the month of AprilThere was an improvement of growth in case of the anti-infectives segment, being the largest category in the Indian pharmaceutical market c...
- Domestic drug market to grow by 13 per cent in 2013: ResearchThe 72,000-crore domestic drug market could grow between 11% and 13% in 2013, according to projections by pharma market research firms.
Load More
